華潤醫藥(03320.HK)附屬華潤醫藥商業擬集資不逾10億元人幣
華潤醫藥(03320.HK)公布,其全資附屬公司華潤醫藥商業集團的潛在發行股份,已於北京產權交易所啟動投標程序,計劃集資不逾10億元人民幣,將用於為未來的併購提供資金、建立物流基礎設施或償付未償還銀行貸款。
華潤醫藥商業擬向不超過12家投資者發行股份,外部投資者將持擴大後股本15%至25%,潛在發行價格不低於華潤醫藥商業經備案的資產評估結果,並以公開摘牌結果為準,現有股東北京醫藥集團及華潤醫藥投資將視增資情況,決定是否以非公開方式同步參與潛在發行。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.